Clinical Trial Update: Palbociclib + Ganitumab In Ewing Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial of palbociclib plus ganitumab in Ewing sarcoma has been terminated with results posted in July 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Ewing Sarcoma Recurrent

Drugs mentioned

• Ganitumab (ganitumab)
• Palbociclib (palbociclib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Ewing Sarcoma, Ewing's Sarcoma Recurrent | Phase 2 | Status: TERMINATED | Results posted: 2024-07-17